Aspen Aerogels INC

Aspen Aerogels announced the staged restart of its East Providence facility following an incident review and appointed its CFO as principal accounting officer.

Aspen Aerogels announced first quarter 2026 financial results, reporting $37.9 million in revenue and a net loss of $23.7 million, while detailing plans for a staged restart of its East Providence facility.

Aspen Aerogels reports that its East Providence manufacturing facility remains offline following an April 8, 2026, explosion.

Aspen Aerogels reported a significant net loss and revenue decline for Q4 and full year 2025, driven by reduced EV demand, and announced a strategic review to optimize its competitive position.

Aspen Aerogels, a leader in sustainability and electrification solutions, announced an amendment to its MidCap credit facility, updating financial covenants for greater flexibility.

Aspen Aerogels reports a Q3 2025 net loss of $6.3 million and significantly lowers its full-year outlook due to challenging U.S. EV demand and a large impairment charge.

Aspen Aerogels reports a significant revenue decline in Q1 2026 amid operational disruptions and reduced EV market demand.

Aspen Aerogels reported a significant net loss for the nine months ended September 30, 2025, driven by declining thermal barrier and energy industrial revenues and substantial impairment charges related to its Statesboro plant.

Aspen Aerogels, Inc. reported a significant net loss of $310.3 million for the first six months of 2025, driven by a large impairment charge and revenue declines in both its Energy Industrial and Thermal Barrier segments.

Aspen Aerogels reports a significant net loss of $301.2 million for Q1 2025, accompanied by a 17% decrease in revenue, driven by reduced thermal barrier sales and restructuring costs.

Aspen Aerogels saw a significant increase in revenue during the third quarter of 2024, driven primarily by its thermal barrier products for the electric vehicle market.

Aspen Aerogels saw a significant increase in revenue and a return to profitability in the second quarter of 2024, primarily driven by growth in the electric vehicle market.

Aspen Aerogels, Inc. filed an amended annual report correcting an inventory balance error, while the underlying financials reveal a significant net loss and revenue decline for 2025.

Aspen Aerogels, Inc. reported a significant net loss of $389.6 million in 2025, driven by a 40% revenue decline and a substantial impairment charge related to its Statesboro Plant.

Aspen Aerogels' 2024 10-K filing reveals significant revenue growth, driven by increased demand for thermal barrier products and sustained performance in the energy industrial sector.

Aspen Aerogels has updated its Code of Business Conduct and Ethics, emphasizing ethical and legal standards for all associates.

William P. Noglows, a Director at Aspen Aerogels Inc., reported transactions involving the acquisition of common stock and stock options.

Director Steven R. Mitchell was granted restricted stock units and stock options as part of the company's annual non-employee director compensation policy.

Director James E. Sweetnam received an annual equity grant of restricted stock units and stock options as part of Aspen Aerogels' non-employee director compensation policy.

Director William P. Noglows received an annual equity grant of restricted stock units and stock options as part of Aspen Aerogels' non-employee director compensation policy.

Director Kathleen Kool received an annual equity grant of restricted stock units and stock options as part of Aspen Aerogels' non-employee director compensation policy.

Director Cari Robinson was granted restricted stock units and stock options as part of Aspen Aerogels' annual non-employee director compensation policy.

Aspen Aerogels' 2026 proxy statement reveals significant 2025 financial underperformance, including a net loss and missed bonus targets, alongside strategic cost reductions and future growth initiatives in energy and EV thermal barriers.

Aspen Aerogels has scheduled its 2025 Annual Meeting to be held virtually on April 30, 2025, and is providing proxy materials to stockholders for voting on key proposals.

Aspen Aerogels achieved record consolidated revenue of $452.7 million in 2024, alongside expanded gross profit margins and positive net income, while also announcing changes to its Board of Directors.

Aspen Aerogels encourages stockholders to support the advisory vote on executive compensation, highlighting the company's strong 2023 financial and operational performance and disagreement with proxy advisory firms' recommendations.

Aspen Aerogels issues a supplement to its proxy statement to correct an error in the number of outstanding shares of common stock as of April 3, 2024.

Aspen Aerogels, Inc. has scheduled its 2024 Annual Meeting to be held virtually on May 30, 2024, and has released proxy materials for stockholder review and voting.

The Vanguard Group reports zero beneficial ownership in Aspen Aerogels Inc. following an internal realignment that disaggregated reporting.

Needham Investment Management, Needham Asset Management, and George A. Needham jointly reported a 5.3% beneficial ownership stake in Aspen Aerogels Inc. as of December 31, 2025.

Oaktop Capital Management II, L.P. has filed an amended Schedule 13G, reporting a 5.35% beneficial ownership stake in Aspen Aerogels, Inc. as of March 31, 2025.

Oaktop Capital Management II, L.P. has filed an amended Schedule 13G, reporting a 5.35% beneficial ownership stake in Aspen Aerogels, Inc. as of March 31, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have reported a combined beneficial ownership of 1.5% of Aspen Aerogels Inc.'s common stock as of December 31, 2024.